XOMA Royalty (XOMA) Income from Continuing Operations (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Income from Continuing Operations came in at 4465000.0 in Q1 2026, up 88.64% year-on-year from 2367000.0 in Q1 2025, and up 117.22% quarter-over-quarter from 25929000.0 in Q4 2025.
XOMA Royalty (XOMA) Income from Continuing Operations (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Income from Continuing Operations across 16 years of filings, most recently posting 4465000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 4465000.0, up 88.64% year-over-year; the trailing twelve-month figure through Mar 2026 was 6046000.0 (up 67.45% YoY), and the FY2025 annual result was 320000.0, down 105.72% from the prior year.
- Income from Continuing Operations came in at 4465000.0 for Q1 2026 at XOMA Royalty, up from 25929000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 14051000.0 in Q3 2025 to a low of 25929000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 5787000.0 (2023), against an average of 5555000.0.
- Across the five-year window, Income from Continuing Operations plunged 392.49% in 2023 and jumped 181.49% in 2025, its largest moves.
- XOMA Royalty's Income from Continuing Operations stood at 6210000.0 in 2022, then slumped by 221.0% to 19934000.0 in 2023, then jumped by 149.09% to 9785000.0 in 2024, then slumped by 364.99% to 25929000.0 in 2025, then surged by 117.22% to 4465000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4465000.0 (Q1 2026), 25929000.0 (Q4 2025), and 14051000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | XOMA Royalty | 5.49 Mn | -60.59 Mn | - | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | -25.93 Mn |
| Sep 30, 2025 | 14.05 Mn |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 9.79 Mn |
| Sep 30, 2024 | -17.24 Mn |
| Jun 30, 2024 | -13.48 Mn |
| Mar 31, 2024 | -10.56 Mn |
| Dec 31, 2023 | -19.93 Mn |
| Sep 30, 2023 | -5.79 Mn |
| Jun 30, 2023 | -5.96 Mn |
| Mar 31, 2023 | -10.17 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | -2.07 Mn |
| Dec 31, 2021 | 29.86 Mn |
| Sep 30, 2021 | -4.44 Mn |
| Jun 30, 2021 | -2.24 Mn |